Reducing the burden of treatment for people with HIV has been a key objective for drug developers since antiretroviral therapy (ART) first reached the market.
Gilead Sciences has said it will soon start a clinical trial in Europe of its twice-yearly HIV injection Sunlenca for pre-exposure prophylaxis (PrEP), a potential successo
The European Commission has become the first regulator worldwide to approved a therapy from Gilead Sciences for people with multidrug-resistant (MDR) HIV infection that only needs to be tak
Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that startup Metsera has launched with an impres
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.